Skip to main content

Advertisement

Table 1 Correlation between clinicopathological features and plakoglobin and E-cadherin expression in 121 patients with breast cancer

From: Circulating tumor cell clusters-associated gene plakoglobin is a significant prognostic predictor in patients with breast cancer

Parameters plakoglobin p value E-cadherin p value
High (n = 21) Low (n = 100) High (n = 71) Low (n = 50)
HR and HER2 status  
 TNBC 4 (19.0%) 35 (35.0%) 0.203 15 (21.1%) 24 (48.0%) 0.003
 non-TNBC 17 (81.0%) 65 (65.0%) 56 (78.9%) 26 (52.0%)
HER2 status
 negative 16 (76.2%) 70 (70.0%)   47 (66.2%) 39 (78.0%) 0.222
 positive 5 (23.8%) 30 (30.0%) 0.792 24 (33.8%) 11 (22.0%)
Age at operation
  ≤ 56 12 (57.1%) 45 (45.0%) 0.344 34 (47.9%) 23 (46.0%) 0.855
  > 56 9 (42.9%) 55 (55.0%) 37 (52.1%) 27 (54.0%)
Menopause
 Negative 10 (47.6%) 38 (38.0%) 0.466 28 (39.4%) 20 (40.0%) 0.950
 Positive 11 (52.4%) 62 (62.0%) 43 (60.6%) 30 (60.0%)
Tumor size
  ≤ 2 cm 2 (9.5%) 15 (15.0%) 0.734 9 (12.7%) 8 (16.0%) 0.607
  > 2 cm 19 (90.5%) 85 (85.0%) 62 (87.3%) 42 (84.0%)
Lymph node status
 Negative 8 (38.1%) 27 (27.0%) 0.304 23 (32.4%) 12 (24.0%) 0.416
 Positive 13 (61.9%) 73 (73.0%) 48 (67.6%) 38 (76.0%)
Nuclear grade
 1, 2 16 (76.2%) 78 (78.0%) 0.857 54 (76.1%) 40 (80.0%) 0.663
 3 5 (23.8%) 22 (22.0%) 17 (23.9%) 10 (20.0%)
Ki67
  ≤ 14% 6 (28.6%) 45 (45.0%) 0.225 30 (42.3%) 21 (42.0%) 0.978
  > 14% 15 (71.4%) 55 (55.0%) 41 (57.7%) 29 (58.0%)
Pathological response
 pCR 7 (33.3%) 41 (41.0%) 0.627 39 (54.9%) 34 (68.0%) 0.187
 non-pCR 14 (66.7%) 59 (59.0%) 32 (45.1%) 16 (32.0%)
Plakoglobin
 Low Not Not   54 (76.1%) 46 (92.0%) 0.023
 High determined determined 17 (23.9%) 4 (8.0%)
E-cadherin
 Negative 4 (19.0%) 46 (46.0%) 0.023 Not Not  
 Positive 17 (81.0%) 54 (54.0%) determined determined
  1. HER2 human epidermal growth factor receptor 2; HR hormone receptor; pCR pathological complete response; TNBC triple-negative breast cancer